Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
| ▸ | MAOB | P27338 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30938635 | 0.79 | TDP1 (0.33) | TDP1UHRF1 | |
| SCHEMBL30590409 | 0.78 | ALDH1A1 (0.39) | SRCKDM4EPTGER4ALDH1A3ALDH1A1 | |
| SCHEMBL335598 | 0.78 | ALDH1A1 (0.39) | SRCKDM4EPTGER4ALDH1A3ALDH1A1 | |
| SCHEMBL13556463 | 0.78 | PTGER4 (0.36) | KDM4EPTGER4ALDH1A3ALDH1A1ALDH3A1 | |
| SCHEMBL29951110 | 0.77 | SRC (0.36) | SRCKDM4EPTGER4ALDH1A3ALDH1A1 | |
| SCHEMBL359521 | 0.75 | ALDH1A1 (0.35) | PTGER4ALDH1A3ALDH1A1TRIM24TRIM33 | |
| SCHEMBL31002342 | 0.75 | ALDH1A1 (0.35) | PTGER4ALDH1A3ALDH1A1TRIM24TRIM33 | |
| SCHEMBL335730 | 0.75 | ALDH1A3 (0.41) | KDM4EPTGER4ALDH1A3ALDH1A1CYP2A6 | |
| SCHEMBL335743 | 0.75 | SRC (0.35) | SRCKDM4EPTGER4ALDH1A3ALDH1A1 | |
| SCHEMBL38662682 | 0.75 | ALDH1A3 (0.41) | KDM4EPTGER4ALDH1A3ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511253-B | Synthesis method of On-DNA tetrahydro-beta-carboline compound in construction of DNA coding compound library | 上海药明康德新药开发有限公司 | 2023-10-13 | — | — | CN | claimed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| US-20240376106-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2024-11-14 | — | — | US | disclosed |
| US-12084443-B2 | Process of preparing a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4355729-A1 | AZETIDINYL COMPOUNDS COMPRISING A CARBOXYLIC ACID GROUP FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Celgene Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024052692-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119451-A1 | Novel Benzamide Derivatives | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | US | disclosed |
| WO-2007071956-A1 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077387-A2 | NOVEL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270714-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | SRC 3247/4885KDM4E 383/4885PTGER4 1672/4885 |
| US-20240376106-A1 | PROCESS OF PREPARING A PD-1/PD-L1 INHIBITOR | PDCD1, CD274, PDCD1LG2 | SRC 1122/4885KDM4E 459/4885PTGER4 4873/4885 |
| US-20080119451-A1 | Novel Benzamide Derivatives | HDAC1, HDAC11, HDAC2 | SRC 4008/4885KDM4E 265/4885PTGER4 3139/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | SRC 1773/4885KDM4E 890/4885PTGER4 2248/4885 |
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | SRC 850/4885KDM4E 3689/4885PTGER4 464/4885 |
| US-11919879-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, LPAR5, S1PR2 | SRC 3247/4885KDM4E 383/4885PTGER4 1672/4885 |
| US-12084443-B2 | Process of preparing a PD-1/PD-L1 inhibitor | PDCD1, CD274, PDCD1LG2 | SRC 1122/4885KDM4E 459/4885PTGER4 4873/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | SRC 1863/4885KDM4E 1090/4885PTGER4 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.